Chiral Quest receives U.S. patent for DIOP* ligand family
DIOP* ligand differs from well-known DIOP ligand in its conformational stability. Methyl groups and other substituents in DIOP* are oriented in equatorial positions. This conformational difference has produced a dramatic increase of enantioselectivity for the hydrogenation of enamides. Rhodium-complexes of DIOP* form efficient catalysts for the asymmetric hydrogenation of enamides.
Chiral bisphosphines are the sixth family of ligands to be added to Chiral Quest's patent portfolio.
"We are the only life sciences chiral chemistry company in the market with proprietary ligands for chiral reactions representing each class of important chiral phosphines," commented Alan Roth, Ph.D., President and Chief Executive Officer of Chiral Quest. "The addition of this patent to our estate further validates our technology."
"The DIOP* ligand family is very effective in producing chiral amines," remarked Professor Xumu Zhang, CTO of Chiral Quest.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.